How do you measure success in therapy? An evidence‑based guide
By TherapyNearMe.com.au. General information only; not a substitute for individual medical or psychological advice. If you are in crisis, call 000. For 24/7 support: Lifeline 13 11 14; Beyond Blue 1300 22 4636.
Why this question matters
“Feeling better” is important, but therapy succeeds when symptoms fall, function improves, life quality rises, and goals meaningful to the client are reached—with benefits that last and avoid harm. Modern services use measurement‑based care (MBC) and routine outcome monitoring (ROM) to track these dimensions session‑by‑session and to adapt treatment when progress stalls (Fortney et al., 2017; Lambert, 2010; Kazdin, 2007).
The five outcome domains
- Symptoms (e.g., depression, anxiety, PTSD, substance use).
- Functioning and participation (work/study, social roles, daily activities).
- Well‑being/quality of life (positive affect, life satisfaction).
- Goal attainment (client‑defined, contextualised change).
- Safety and adverse effects (deterioration, suicidality, side‑effects).
Best practice includes one brief instrument for symptoms, one for functioning/well‑being, one alliance/process tool, and a goal measure, reviewed every 2–4 weeks (Fortney et al., 2017; Priebe et al., 2011).
Commonly used validated tools (examples)
Symptoms
- PHQ‑9 (depression) (Kroenke, Spitzer and Williams, 2001).
- GAD‑7 (generalised anxiety) (Spitzer et al., 2006).
- DASS‑21 (depression/anxiety/stress) (Lovibond and Lovibond, 1995).
- OQ‑45 Symptom Distress (Lambert et al., 2004).
Functioning and well‑being
- WHODAS 2.0 (disability/functioning) (WHO, 2010).
- WEMWBS (mental well‑being) (Tennant et al., 2007).
- CORE‑OM (global distress and functioning) (Evans et al., 2002).
Goal attainment
- Goal Attainment Scaling (GAS)—client‑specific, structured (Kiresuk and Sherman, 1968).
Process/alliance
- Working Alliance Inventory (WAI) (Bordin, 1979; Horvath and Symonds, 1991).
- Session Rating Scale (SRS) and Outcome Rating Scale (ORS) for Feedback‑Informed Treatment (Miller, Duncan and Johnson, 2000; Miller et al., 2003).
Risk/safety (examples)
- Brief suicide risk screen (e.g., C‑SSRS triage), adverse effect checklists; track unplanned discharges/deterioration (Lambert, 2010).
Interpreting change: more than a raw score
- Clinically significant change (CSC): post‑treatment functioning moves into the non‑clinical range on a validated instrument (Jacobson and Truax, 1991).
- Reliable change (RCI): the size of change exceeds what could be expected from measurement error (Jacobson and Truax, 1991).
- Minimal clinically important difference (MCID): the smallest change that patients perceive as beneficial; varies by measure and baseline severity (Priebe et al., 2011).
- Deterioration: reliable worsening on any outcome; must be monitored and acted upon (Lambert, 2010).
Combine RCI + CSC for high‑confidence classification: recovered, improved, unchanged, or deteriorated(Jacobson and Truax, 1991; Lambert, 2010).
Process matters: the alliance and early response
The therapeutic alliance (agreement on goals/tasks and the bond) is consistently linked to outcomes across modalities (Horvath and Symonds, 1991; Flückiger, Del Re, Wampold and Horvath, 2018). Early change over sessions 1–4 predicts end‑of‑treatment results; monitoring enables timely adjustments (Howard, Kopta, Krause and Orlinsky, 1986; Hansen, Lambert and Forman, 2002). Feedback‑informed approaches that use ORS/SRS or OQ‑Analyst to flag “not‑on‑track” cases reduce deterioration and improve outcomes (Lambert, 2010; Anker, Duncan and Sparks, 2009).
A practical measurement blueprint for individuals and services
- Before therapy (baseline): pick 2–3 instruments relevant to your needs (e.g., PHQ‑9 + WEMWBS + SRS/WAI). Add 1–3 personal goals expressed behaviorally and contextually (GAS).
- Every session: record a micro‑outcome (ORS) and alliance (SRS) or brief WAI; note risk/safety.
- Every 2–4 weeks: re‑administer symptom/well‑being tools. Plot a simple graph to show trend.
- Decision rules:
- On‑track: continue; begin relapse‑prevention once CSC achieved.
- Off‑track or flat after 3–6 sessions: review formulation; consider intensifying, switching modality, adding skills group, or addressing barriers (attendance, practical stressors).
- Deterioration: safety review; supervision; step‑up care; consider psychiatric consult.
- End of therapy: re‑score; classify using RCI/CSC; review goal attainment; create a well‑being plan (relapse signatures, booster options).
- Follow‑up (1–3 months): brief re‑check of primary measure(s) and goals to assess maintenance.
What “success” looks like in real life (mini‑case)
Client: Adult with low mood, anhedonia and sleep problems affecting work attendance.
Measures: PHQ‑9 (symptoms), WHODAS‑12 (function), WEMWBS (well‑being), SRS (alliance), two GAS goals (sleep routine; two social contacts/week).
Course: By session 4, PHQ‑9 down 4 points (early response); sleep routine at 4/7 nights; alliance strong. At session 8, RCI met on PHQ‑9; CSC achieved on WEMWBS; GAS goals rated +1 and +2 (better than expected). Work attendance back to baseline; relapse‑prevention plan drafted.
Interpretation: Symptom reduction + functional gains + goal attainment + strong alliance + maintenance plan = success under multiple lenses.
How many sessions does success take?
There is no one‑size number. Dose–response curves show most change early, then a taper; many clients improve by 8–12 sessions, while others need longer courses or stepped care (Howard et al., 1986; Hansen, Lambert and Forman, 2002). Complexity (comorbidity, trauma, social determinants) stretches timelines; measurement guides pacing rather than forcing discharge.
Choosing measures wisely (clinically and culturally)
- Prefer brief, validated, free/low‑cost tools where possible.
- Ensure reading level and language access; provide interpreters and culturally adapted tools when needed.
- Share results collaboratively; numbers are a conversation starter, not a grade.
- Store data securely; use aggregated dashboards for quality improvement (Priebe et al., 2011).
Risks and ethical guardrails
- Avoid measurement over‑load that crowds out therapy time.
- Watch for gaming (rushing ratings) and ceiling effects; triangulate with goals and narrative feedback.
- Track harms explicitly: deterioration, dropout, iatrogenic effects (Lambert, 2010).
- Use measures to adapt, not to blame; align with informed consent and privacy laws.
Quick checklist you can print
- Baseline symptom and well‑being/function measures chosen.
- Two client‑defined goals captured (GAS or equivalent).
- Alliance rated each session (SRS/WAI).
- Symptom/well‑being tools repeated every 2–4 weeks.
- Graph shows trend; decision rules agreed.
- RCI/CSC calculated at discharge.
- Relapse‑prevention plan created.
- Follow‑up check scheduled.
References
Anker, M.G., Duncan, B.L. and Sparks, J.A. (2009) ‘Using client feedback to improve couple therapy outcomes: A randomized clinical trial in a naturalistic setting’, Journal of Consulting and Clinical Psychology, 77(4), pp. 693–704.
Bordin, E.S. (1979) ‘The generalizability of the psychoanalytic concept of the working alliance’, Psychotherapy: Theory, Research & Practice, 16(3), pp. 252–260.
Evans, C., Connell, J., Barkham, M., Margison, F., McGrath, G., Mellor‑Clark, J. and Audin, K. (2002) ‘Towards a standardised brief outcome measure: psychometric properties and utility of the CORE‑OM’, British Journal of Psychiatry, 180(1), pp. 51–60.
Flückiger, C., Del Re, A.C., Wampold, B.E. and Horvath, A.O. (2018) ‘The alliance in adult psychotherapy: A meta‑analytic synthesis’, Psychotherapy, 55(4), pp. 316–340.
Fortney, J.C., Unützer, J., Wrenn, G., Pyne, J.M., Smith, G.R., Schoenbaum, M. and Harbin, H.T. (2017) ‘A tipping point for measurement‑based care’, Psychiatric Services, 68(2), pp. 179–188.
Hansen, N.B., Lambert, M.J. and Forman, E.M. (2002) ‘The psychotherapy dose‑response effect and its implications for treatment policy’, Clinical Psychology: Science and Practice, 9(3), pp. 329–343.
Horvath, A.O. and Symonds, B.D. (1991) ‘Relation between working alliance and outcome in psychotherapy: A meta‑analysis’, Journal of Counseling Psychology, 38(2), pp. 139–149.
Howard, K.I., Kopta, S.M., Krause, M.S. and Orlinsky, D.E. (1986) ‘The dose‑effect relationship in psychotherapy’, American Psychologist, 41(2), pp. 159–164.
Jacobson, N.S. and Truax, P. (1991) ‘Clinical significance: A statistical approach to defining meaningful change in psychotherapy research’, Journal of Consulting and Clinical Psychology, 59(1), pp. 12–19.
Kazdin, A.E. (2007) ‘Evidence‑based treatment and practice: new opportunities to bridge clinical research and practice, enhance the knowledge base, and improve patient care’, American Psychologist, 62(2), pp. 85–100.
Kiresuk, T.J. and Sherman, R.E. (1968) ‘Goal Attainment Scaling: A general method for evaluating comprehensive community mental health programs’, Community Mental Health Journal, 4(6), pp. 443–453.
Kroenke, K., Spitzer, R.L. and Williams, J.B.W. (2001) ‘The PHQ‑9: Validity of a brief depression severity measure’, Journal of General Internal Medicine, 16(9), pp. 606–613.
Lambert, M.J. (2010) Prevention of Treatment Failure: The use of outcome measures to identify and help not‑on‑track patients. Washington, DC: American Psychological Association.
Lovibond, S.H. and Lovibond, P.F. (1995) Manual for the Depression Anxiety Stress Scales (DASS). 2nd edn. Sydney: Psychology Foundation.
Miller, S.D., Duncan, B.L. and Johnson, L.D. (2000) ‘The Session Rating Scale 3.0: The therapeutic alliance in a brief, consumer‑based format’, Psychotherapy Bulletin, 36(1), pp. 1–4.
Miller, S.D., Duncan, B.L., Brown, J., Sparks, J.A. and Claud, D. (2003) ‘The Outcome Rating Scale: A brief measure of therapeutic change in an outpatient setting’, Administration and Policy in Mental Health and Mental Health Services Research, 30(6), pp. 523–541.
Priebe, S., McCabe, R., Bullenkamp, J., Hansson, L., Lauber, C., Martinez‑Leal, R., et al. (2011) ‘Patient‑reported outcome data in mental health: Advantages and limitations’, British Journal of Psychiatry, 199(4), pp. 259–261.
Spitzer, R.L., Kroenke, K., Williams, J.B.W. and Löwe, B. (2006) ‘A brief measure for assessing generalized anxiety disorder: The GAD‑7’, Archives of Internal Medicine, 166(10), pp. 1092–1097.
Tennant, R., Hiller, L., Fishwick, R., Platt, S., Joseph, S., Weich, S., et al. (2007) ‘The Warwick‑Edinburgh Mental Well‑being Scale (WEMWBS): Development and UK validation’, Health and Quality of Life Outcomes, 5, 63.
World Health Organization (2010) Measuring Health and Disability: Manual for WHO Disability Assessment Schedule (WHODAS 2.0). Geneva: WHO Press.
How to cite this article
Therapy Near Me (2025) ‘How do you measure success in therapy? An evidence‑based guide’. Available at: https://therapynearme.com.au
